Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)
Dermatology
An infographic exploring the process of allergen sensitization and the impact it may have on the development of atopic comorbidities in children with AD.
PN and AD: Distinct Diseases with Underlying Type 2 Inflammation
Dermatology
Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.
Cutaneous Manifestations in AD & PN: Role of Type 2 Inflammation video
Dermatology
Type 2 inflammation in the distinct cutaneous manifestations of atopic dermatitis and prurigo nodularis – a clip from the ADVENT symposium at AAD 2023.
Changes in nerve density and dysfunction of the neuroimmune axis drive pruritus in prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.
Presentation of atopic dermatitis and prurigo nodularis, and the impact of PN as an intensely pruritic disease – Clip from the ADVENT symposium at AAD 2023.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.